All In Biotech

Drug Trial Radar · NCT02750332

Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)

A Single Center, Single-Dose, Open-Label, Randomized Study to Compare the Bioavailability of an Oral Test Formulation Containing Nitisinone 10 mg in at Least 16 Healthy Male and Female Subjects Under Fasting and Fed Conditions

Last checked: Nov 19, 2026Latest source record: Mar 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Nov 2015

Primary completion

Dec 2015

Study completion Jan 2016

Sponsor

Lead sponsor
Cycle Pharmaceuticals Ltd.Industry
Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the bioavailability of the Test Product, Nitisinone 10 mg Tablet, under fasting and fed conditions (food-effect).

Conditions

  • Hereditary Tyrosinemia, Type I

Interventions

  • NitisinoneDrug

    A single oral dose of Nitisinone 10 mg Tablet will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: 0 - 120 hours post-dose
  2. Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))Time frame: 0 - 120 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)

    Bloemfontein, Free State, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.